Could Argenx SE – American Depositary Shares (NASDAQ:ARGX) Change Direction After More Shorts?

September 16, 2018 - By Brian Ramirez

The stock of Argenx SE – American Depositary Shares (NASDAQ:ARGX) registered an increase of 8.79% in short interest. ARGX’s total short interest was 269,800 shares in September as published by FINRA. Its up 8.79% from 248,000 shares, reported previously. With 76,600 shares average volume, it will take short sellers 4 days to cover their ARGX’s short positions.

The stock increased 4.90% or $4.38 during the last trading session, reaching $93.78. About 128,278 shares traded or 34.04% up from the average. argenx SE (NASDAQ:ARGX) has risen 329.81% since September 16, 2017 and is uptrending. It has outperformed by 314.19% the S&P500.

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody therapies for the treatment of autoimmune diseases and cancer. The company has market cap of $3.10 billion. The companyÂ’s lead clinical stage product candidates include ARGX-113, a product in Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis and immune thrombocytopenia; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of hematological cancers, such as T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It currently has negative earnings. It is also developing ARGX-111 to treat solid tumors with MET amplification; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia.

More notable recent argenx SE (NASDAQ:ARGX) news were published by: Seekingalpha.com which released: “Argenx receives feedback on Phase 3 clinical trial for efgartigimod in generalized myasthenia gravis” on August 29, 2018, also Nasdaq.com with their article: “argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology …” published on August 22, 2018, Benzinga.com published: “32 Stocks Moving In Friday’s Mid-Day Session” on September 14, 2018. More interesting news about argenx SE (NASDAQ:ARGX) were released by: Benzinga.com and their article: “The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs” published on September 09, 2018 as well as Nasdaq.com‘s news article titled: “argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia …” with publication date: September 06, 2018.

argenx SE (NASDAQ:ARGX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.